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Background and aims
Results
Tobacco smoking (Figure 1) is a major cause of cardiovascular diseases
(CVD), and appears to have a multiplicative interaction with the other major
CVD risk factors (lipids, hypertension, diabetes and others present in the
metabolic syndrome (MetS). Several omics have analyzed the separate
effects of tobacco smoking on the genome, epigenome, transcriptome,
metabolome, etc. However an integrated omics approach can help to better
understand the crosstalk between tobacco smoking and the genome.
We have analyzed participants recruited from the PREDIMED Plus-Valencia
study (located on the eastern Mediterranean coast, Spain). Eligible
participants, recruited from several primary care health facilities in the
Valencia field center, were community-dwelling adults (men, 55–75 years,
women, 60–75 years) with a body-mass index (BMI) in the overweight or
obesity range ((BMI) ≥ 27 and <40 kg/m2) and had at least three
components of the metabolic syndrome. randomized participants included
in the PREDIMED Plus trial. DNA and RNA were isolated from blood. The
GWAS for tobacco smoking was carried out in all the participants with DNA
available (n=450), EWAS and TWAS were carried out in a subsample of 88
participants having this analysis available. Anthropometric variables  as well
as tobacco smoking and other lifestyle variables were determined by trained
staff and follow the PREDIMED Plus operations protocol detailed in the study
Web site (http://www.predimedplus.com/). Smoking status was assessed
according to the WHO classification (including current smokers, former
smokers (including former smokers <1 year, from 1 to 5 years and more than
5 years) and never smokers. These subjects were aged 55 to 75 years, mean
age 65+/-5 years, all with metabolic syndrome.
For GWAS, genetic association analyses were performed using PLINK v1.9
using and additive model. Subjects were re-classified into current smokers
and non-smokers. Coefficients for the minor allele were estimated.
Unadjusted and adjusted (for sex and age or for additional variables) general
linear models were fitted. We used the conventional threshold of p < 5 ×
10−8 for genome-wide statistical significance. Since this threshold is very
conservative for a small sample size, SNPs with p-values below 1 × 10−5
were also considered suggestive of genome-wide significance. SNPs were
rank-ordered according to the minimum p-value in the genetic models.
2. RNA isolation and TWAs
RNA was isolated from fresh blood at baseline in 88 subjects (44 males and
44 females) with the Promega device and kit. RNA integrity was assayed by
means of the 2100 Bioanalyzer with Eukaryote total RNA Nano Assay
(Agilent Technologies, Santa Clara, CA, USA (Figure 10)). RNA integrity
number (RIN) served as RNA integrity parameter (selection criteria RIN ≥
9.0).Microarray experiments were performed at the Central Research Unit
(University of Valencia). GeneChip Human Gene 2.0 ST Array containing over
41,000 transcripts and represent over 36,000 well-characterized human
genes (Affymetrix, Santa Clara, CA, USA) was used for microarray analysis.
GeneChip Operating Software supplied by Affymetrix was used to
generate.CEL files. Partek Genomic suite was used for gene expression
analysis. Multivariate models were used to adjust for potential confounders
including batch effect, sex, age, leukocyte counts, etc.
Figure 1: Tobacco smoking)
Several GWAS have analyzed genetic polymorphisms associated with a
higher risk of smoking, among them, the work carried out by Erzurumluoglu
et al (Molecular Psychiatry, 2018), in more than 600,000 participants,
identifying 40 new loci associated with smoking behavior (Figure 2),
however, the Mediterranean population has been scarcely studied.
In the EWAS the top-ranked differentially methylated CpG sites were:
cg05575921 in the AHRR (aryl hydrocarbon receptor repressor) gene
(P=2.73E-14), and the cg03636183 in the F2RL3 (coagulation factor II
(thrombin) receptor-like 3) gene (P=6.90E-09), replicating previous finding of
the hypomethylation of the AHRR and F2RL3 sites in smokers.
In the TWAS, we identified the GPR15 gene as the most differentially
expressed between smokers and non-smokers (6.43E-19). Likewise, the
LRRN3 gene (P=1.41E-08) was another differentially expressed gene, in
agreement with previous findings. For the LRRN3 gene we detected very
consistent results both in the TWAS and in the EWAS analysis. There are
preliminary results in a pilot study and more work has to be done, also
increasing sample size.
Future research will focus on omics-integration analyses, as well as on
analysis de modulation of the effects by other environmental factors such as
diet, physical activity, etc.
Another consistent association has been found with coagulation factor II
(thrombin) receptor-like 3 (F2RL3, cg03636183). Hypomethylation of this
gene has been associated with smoking in several studies and in different
populations mimicking the AHRR effects (Figure 6 and Figure 7).
Methods
3. Epigenome-wide methylation analysis
We performed genome-wide DNA methylation (EWAS) in the same 88
subjects using the Illumina Infinium 850K MethylationEPIC array (Figure 11).
Differential methylation (M-values) was statistically analyzed with Partek
Genomic Suite using ANCOVA models adjusted for potential confounders
including batch effect, age, BMI, diabetes and leukocyte counts, among
others.
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Likewise, several epigenome-wide association studies (EWAS), have
consistently identified several differentially methylated loci associated with
tobacco smoking (Figure 3).
Several individual studies and meta-analyses in different populations have
reported a strong hypomethylation signal in the CpG cg05575921 locus
depending on the smoking status . Among these studies, we show specific
data in the REGICOR study, a population study carried out in the
Mediterranean population (Figure 4), as well as the participants in the MESA
study (Figure 5).
In addition to these consistent loci, other methylated loci have been
associated with tobacco smoking depending on the population analyzed.
On the other hand, some transcriptomic-wide studies (TWAS) have
identified several gene differentially expressed in blood from smokers vs
non-smokers. Among these meta-analysis, Huan et al (Hum Mol Genet,
2016) analyzing 6 cohorts identified several differentially expressed genes
including the LRRN3 (Leucine Rich Repeat Neuronal 3) (Figure 8).
However, these studies have used isolated omics, and a multi-omics
integration for tobacco smoking in needed. Therefore, our aim was to
undertake a multi-omics analysis to better understand the genetic factors
associated with current smoking in older subjects with MetS, as well as the
effect of smoking on DNA methylation and on gene expression.
We carried out a study using genomics, epigenomics and transcriptomics
(Figure 9) in subjects with MetS from the Mediterranean population.
Table 1 shows the main characteristics of the Predimed Plus-Valencia study
participants at baseline. Prevalence of current smokers was 11.4%.
A GWAS for current smoking was carried out on these subjects. Among the
top-ranked SNPs (at P<1x10E-5 in a model adjusted for age and sex) (Table 2)
we found the rs7942698-SLC1A2 (in a transporter essential for clearing
glutamate from neuronal synapses) and the rs776404-NRG1 (Neuregulin
signaling pathway), both previously linked to addictions and smoking.
Figure 3
Figure 4: Methylation of the
AHRR gene and other genes
depending on the smoking
status in the REGICOR study
(Epigenetics, 2015).
Figure 5: EWAS for
methylation status





of the AHRR and F2RL3
locus by smoking (Lee et al,
PlosOne, 2017).
Figure 7: Hypomethylation
of the AHRR and F2RL3
locus by smoking (Fasanelli
et al, Nat Comunications,
2015).
Figure 8: Differentially
expressed genes in current
smokers vs never smokers
(Huan et al, 2016).
Figure 9: Multi-omics used
1 Genomic analyses and GWAS
DNA was isolated from blood (buffy-coats), and  high-density genotyping
was performed at the University of Valencia using the Infinium
OmniExpress-24 v1.2 BeadChip genotyping array (Illumina Inc., San Diego,
CA, USA), according to the manufacturer’s protocol with appropriate quality
standards. This array captures 713,599 markers. Allele detection and
genotype calling were performed in the GenomeStudio genotyping module
(Illumina, Inc., San Diego, CA, USA). Data cleaning was performed using
standard analysis pipelines implemented in the Phyton programing language
using the Numpy library modules combined with the PLINK. From the initial
full set, those SNPs not mapped on autosomal chromosomes were filtered
out. In addition, SNPs with a minor allele frequency (MAF) < 0.01 or those
that deviated from expected Hardy-Weinberg equilibrium (p < 1.0 × 10−5)
were removed.
Figure 10: Transcriptomic analysis





Table 2: Top-ranked SNPs
for tobacco smoking
(additive model adjusted
for sex and age)
